The antihyperlipidaemic FM-VP4 reduces arterial plaque development

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1243, 2000-01, pp. : 6-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment with a Cholesterol Absorption Inhibitor (FM-VP4) Reduces Body Mass and Adipose Accumulation in Developing and Pre-Obese Mice

By Thornton Sheila   Warburton Corinna   Wasan Kishor   Kozlowski Piotr  

Drug Development and Industrial Pharmacy, Vol. 33, Iss. 10, 2007-10 ,pp. : 1058-1069

Informa Healthcare

Access to resources Recommend Favorite

HSP-65 vaccination reduces plaque progression in mice

By  

Inpharma, Vol. 1, Iss. 1362, 2002-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Antihyperlipidaemic drug use in Italy

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 275, 2000-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Oral glucose tolerance test reduces arterial baroreflex sensitivity in older adults

By Madden Kenneth M.   Tedder Gale   Lockhart Chris   Meneilly Graydon S.  

Canadian Journal of Physiology and Pharmacology, Vol. 86, Iss. 3, 2008-03 ,pp. : 71-77

NRC Research Press

Access to resources Recommend Favorite

HMOs linked with better antihyperlipidaemic compliance

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 267, 2000-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite